¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69

Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years

Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans

Guest Editorial by Nora Volkow - Advancing Reduction of Drug Use as an Endpoint in Addiction Treatment Trials

For many people trying to recover from a substance use disorder, perhaps for the majority, abstinence may be the most appropriate treatment objective. But complete abstinence is sometimes not achievable, even in the long-term, and there is a need for new treatment approaches that recognize the clinical value of reduced use.

The association between buprenorphine doses above 16 milligrams and treatment retention

This guideline was developed to help clinicians determine when the risks of continued BZD prescribing outweigh the benefits for a given patient and how to safely taper the medication when indicated. Existing guidelines generally recommend limiting duration of BZD use to 2-4 weeks (except for limited conditions such as severe treatment-resistant generalized anxiety disorder, complex seizure disorders, spasticity, and sleep disorders involving abnormal movements). However, long-term BZD prescribing remains prevalent.

Guest Editorial: New Clinical Practice Guideline - Benzodiazepine Tapering

Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year Mortality

Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders

Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl